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Conclusions: Further research is warranted to deﬁne the role of theT-
GFBR1 Int7G24A gene in customized treatments.
 N OR (95% CI) P
ARM 
Control 126 0.57 (0.34-0.93) 0.02
Low ERCC1 114 1 ref  
High ERCC1 84 0.80 (0.46-1.39) 0.54
PS 
o 124 1 ref  
1 200 0.55 (0.35-0.85) 0.004
XRCC3 
ThrThr 138 0.82 (0.51-1.32) 0.42
ThrMet 155 1 ref  
MetMet 31  0.30 (0.12-0.72) 0.007
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and Types of Local Advanced and Metastatic NSCLC
Turan, Onur1 Akkoclu, Atila1 Coker, Canan2 
1 Dokuz Eylul University the Faculty of Medicine Chest Diseases 
Department, Izmir, Turkey 2 Dokuz Eylul University the Faculty of 
Medicine Biochemistry Department, Izmir, Turkey 
Plasma lactate dehydrogenase (LDH) is a biochemical parameter sup-
posed to get elevated in lung cancer, especially in advanced tumors. 
LDH is an important enzyme which catalyses lactate formation from 
pyruvate in anaerobic metabolism. It is called to be a non-speciﬁc 
indicator of dying tumor cells by reﬂecting their rapid turnover. In our 
study, we aimed to show that plasma LDH levels are found to be high 
in lung cancer and LDH can reﬂect the stage and prognosis of tumor. 
We detected 40 patients with new diagnosis of non small cell lung 
cancer. We chose a control group of 40 patients with chronic obstruc-
tive pulmonary disease (COPD). In lung cancer group, we chose the 
patients without history of COPD; also COPD patients elected for con-
trol group didn’t have diagnosis of lung cancer. The history of smoking 
wasn’t thought to affect the results of our study as it was an intersection 
of both groups. Gender and age were found to be statistically similar 
for each group. We accepted the normal plasma level of LDH between 
240-480 U / l.
The mean level of LDH was 606,5 U / l in lung cancer group when it 
was found as 387,3 U / l in control group which was statistically sig-
niﬁcant (p=0,002). In control group, we found 7 patients having a high 
value of LDH (15 %); it seemed to be high in 20 patients of lung cancer 
group (%50).
Afterwards, NSCLC group was examined if LDH levels differed ac-
cording to stage and tumoral type. By using TNM staging, 26 of 40 
patients were found to be in stage IV, 7 in stage IIIb and 7 in stage 
IIIa. Plasma level of LDH was high in 14 of 26 stage IV patients, 3 in 
7 stage IIIb and 3 in 7 stage IIIa. We examined mean LDH levels ac-
cording to stages of tumors: 453.8 in stage IIIa, 508.3 in stage IIIb, and 
684.2 in stage IV, which shows that LDH is high in advanced NSCLC. 
However, LDH levels weren’t found statistically signiﬁcant according 
to stages. We think that the heterogen distribution of tumor stages can 
be the reason of it.
There were 15 squamous cell, 15 adenocarcinoma and 10 uncertain 
histopathological type of NSCLC in lung cancer group. LDH was high 
in 6 of 15 squamous cell, in 8 of 15 adenocarcinoma and in 6 of other 
10 NSCLC. The mean LDH level was 504.1 in squamous cell, 642.5 in 
adenocarcinoma and 673 in other NSCLC; we can see that LDH levels 
are higher in adenocarcinoma. This data achieved according to tumor 
types wasn’t found statistically signiﬁcant; the limited number of the 
universe can explain this result.
The results of our study supports that plasma LDH levels are higher 
in patients with lung cancer. Although LDH levels were found to be 
high in advanced NSCLC and in adenocarcinoma,but statistically not 
signiﬁcant, more advanced studies with a high number and homogen 
distribution of patients should have done to conﬁrm these results. 
P2-106 BSTB: Prognostic Factors Posters, Tue, Sept 4 
Gender differences in non-small cell lung cancer (NSCLC) 
patients (p): A retrospective study based in Spanish Lung Cancer 
Group(SLCG) trials.
Viñolas, Nuria1 Isla, Dolores2 Felip, Enriqueta3 Garrido, Pilar4 Garcia-
Campelo, Rosario5 Lianes, Pilar6 Bover, Isabel7 Terrasa, Josefa8 Vadell, 
Catalina9 Rosell, Rafael10 
1 Hospital Clínic i Provincial, Barcelona, Spain 2 Hospital Clínico Loz-
ano Blesa, Zaragoza, Spain 3 Hospital Vall D’hebron, Barcelona, Spain 
4 Hospital Ramon Y Cajal, Madrid, Spain 5 Hospital Juan Canalejo, 
La Coruña, Spain 6 Hospital De Mataró, Mataró, Spain 7 hospital son 
llatzer, Palma de Mallorca, Spain 8 Hospital Son Dureta, Palma de 
Mallorca, Spain 9 Hospital De Manacor, Palma Mallorca, Spain 10 ICO-
Hospital Germans Trias i Pujol, Badalona, Spain 
Background: There are some data supporting differences by sex 
in lung cancer. So we undertook a retrospective analysis of clinico-
pathologic and genetic features in women (W) with advanced NSCLC 
participating in ﬁrst-line chemotherapy (CT) SLCG trials. 
Methods: Data on age, histology, PS, CT schedule, XRCC3 (DNA 
repair capacity gene) single nucleotide polymorphisms (SNPs) as-
sessment in DNA from peripheral blood lymphocytes, CT outcomes, 
survival and disease free-survival were obtained. 
Results: 1125 p included in 4 SLCG trials from 2001 to 2005 treated 
with CT based on CDDP/GEM, CDDP/DOC or DOC/GEM were 
analysed. 167 p (14.9%) were W. W were signiﬁcantly younger than 
men (M) (median, 57 yrs vs 61 yrs, P<0.0001). Adenocarcinoma 
subtype was more predominant in W than in men (76% vs 47%, 
P<0.0001). There were not signiﬁcant differences by sex considering 
PS (0/1)(P<0.85), stage (IIIB/IV)(P<0.18) or overall response rate 
(P<0.45). Median time to progression (TTP) was 6.8 months (m) vs 5.3 
m (P<0.009) in favour of W. Median overall survival (OS) was 11.4 
m for W vs 9.1 m for M (P<0.001). No differences were found in the 
subgroup of patients receiving DOC/GEM probably due to the small 
number of patients. XRCC3 SNPs were distributed similarly between 
sexes. SNPs genotype of both XRCC3 241Met/Met and Thr/Met 
correlates with better survival in W vs M (P<0.05 and P<0.008). In a 
multivariate analysis, sex was an independent predictive marker for 
both OS (HR 1.5, 95% CI 1.2-1.9, P<0.0001) and TTP (HR 1.4, 95% 
CI 1.1-1.7, P<0.001), others independent variables found were PS, age, 
type of CT, but not XRCC3 241 genotype.
Conclusions: In this retrospective analysis of four SLCG trials, women 
with NSCLC were found to have better prognosis than men. Results 
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from this study should emphasize the need for the inclussion of stratiﬁ-
cation by gender in future clinical trials. 
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Value of Thyroid Transcription Factor-1 in Identification of the 
Prognosis of Bronchioloalveolar Carcinoma
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Objective: To evaluate the expression and clinical signiﬁcance of cyto-
keratin subtypes (CK7,CK20) and thyroid transcription factor-1 (TTF-
1) in bronchioloalveolar carcinoma (BAC), furthermore, investigate the 
value of these factors in identiﬁcation of the prognosis of BAC.
Methods: 81 cases of surgically resected BAC specimens (including 
68 nonmucinous types and 13 mucinous types) were collected from 
The Cancer Hospital of Tianjin Medical University during the period 
from 1990 to 2000. Expression of CK7, CK20 and TTF-1 of them 
was studied by immunohistochemistry. The value of the three factors 
in identiﬁcation of the prognosis of BAC was examined by survival 
analysis. 
Results: No signiﬁcant correlation was found between CK7 positive 
rate and age-groups, clinical stages and pathological subtypes of BAC 
(P>0.05). The positive rate of CK20 was higher in stage I-II and muci-
nous types than that in stage III and nonmucinous types. The positive 
rate of TTF-1 was signiﬁcantly higher in stage III and nonmucinous 
types than that in stage I-II and mucinous types (P<0.05). There was 
a statistically signiﬁcant positive correlation between expression of 
CK7 and TTF-1 (r=0.257, P=0.021). The main prognostic factors were 
TTF-1 expression, clinical stage, tumor diameter and N stage (P<0.05). 
Strata analysis suggested that the survival time of BAC with TTF-1 
positive was superior to that with TTF-1negative in nonmucinous types 
(P=0.009); the survival time of BAC with TTF-1 positive was superior 
to that with TTF-1 negative in stage III (P=0.022). Cox Regression 
suggested that TTF-1 (P=0.035), TNM stage (P=0.000), tumor diameter 
(P=0.034), N stage (P=0.000) were independent factors affecting the 
prognosis. 
Conclusions: There is a statistically signiﬁcant positive correlation 
between expression of CK7 and TTF-1. TTF-1 and CK20 provide a 
new evidence for the molecular staging of BAC. TTF-1, TNM stage, 
tumor diameter and N stage are all independent factors affecting the 
prognosis of BAC.
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Background: Surgical resection is the most effective treatment for 
early stage non-small cell lung cancer. However, even after curative 
resection, many patients develop recurrences. Although the adjuvant 
chemotherapy has recently become the standard of therapy for radi-
cally resected early stage NSCLC, the beneﬁt is modest. Developing 
of new molecular markers could more accurately predict the treatment 
outcome. 
Purpose: We examined whether hypermethylation of tumor suppres-
sor genes DAPK, p16INK4a, APC1A, p14ARF, E-cadherin, MGMT 
and RASSF1A could predict the clinical outcome of 31 patients with 
primary NSCLC after radical surgical resection.
Materials and Methods: The methylation status of candidate genes 
was analyzed by methylation-speciﬁc PCR. Genomic DNA was puri-
ﬁed from tumor tissue and was subsequently treated with sodium 
bisulﬁte to convert unmethylated cytosine bases to uracil. To increase 
the sensitivity we have developed a nested PCR approach. A ﬁrst PCR 
ampliﬁes a larger fragment using primers, which do not discriminate 
between the methylated or wild-type genotype. The second PCR uses 
nested primers, which speciﬁcally amplify either methylated or un-
methylated sequences. Results were visualized by gel electrophoresis. 
Results: Methylation was detected at a frequency of 74.2% for DAPK, 
77.4% for p16INK4a, 74.2% for APC1A, 71.0% for p14ARF, 80.0% 
for E-cadherin, 32.3% for MGMT and 61.3% for RASSF1A. The 
univariate Cox regression model showed that methylation status of 
DAPK, p16INK4a, APC1A, p14ARF, regional lymph node status and 
gender were signiﬁcant risk factors for recurrence of NSCLC (hazards 
ratios, DAPK methylated, 55.26 [95% CI, 1.03 to 2967.62; p=0.048], 
p16INK4a methylated, 4.68 [95% CI, 1.03 to 21.34; p=0.048]; APC1A 
methylated, 0.293 [95% CI, 0.10 to 0.83; p=0.021]; p14ARF methyl-
ated, 0.312 [95% CI, 0.12 to 0.83; p=0.020]; N2, 3.59 [95% CI, 1.24 to 
10.35; p=0.018]; and male, 4.25 [95% CI, 1.22 to 14.87; p=0.023]. The 
stepwise multivariate Cox regression model identiﬁed DAPK methyla-
tion status as the only independent risk factor for recurrence.
Conclusion: Our preliminary results suggest that hypermethylation of 
DAPK could be an important factor in predicting NSCLC recurrence 
but further investigations are needed.
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Background: Bone sialoprotein(BSP) and osteopontin(OPN) have 
been demonstrated predictive of bone metastasis in breast and prostate 
carcinoma, consistent with the proposed role of BSP as a stimulator 
of bone mineralization and OPN in differentiation and activation of 
osteoclasts. Bone metastasis(BM) is often developed in non-small-cell 
lung cancer(NSCLC), but no predictive biomarkers was identiﬁed for 
high risk of metastatic bone dissemination.
Methods: 180 completely resected NSCLC patients(of 38 patients 
subsequently developed BM) were included in the investigation. Paraf-
ﬁn embedded primary tissue of these 180 patients were supplied to 
produced a tissue microarray, and investigated by immunohistochem-
istry for BSP and OPN. Different expressions of these two biomarkers 
